Blanket Purchase Agreement 36F79718D0566-36E79719A0008

The Blanket Purchase Agreement was awarded as a single award by the Department of Veterans Affairs National Acquisition Center to Aimmune Therapeutics, Inc. The potential value of the BPA is $14 million. The BPA is for the procurement of Palforzia, which is intended to reduce the frequency and severity of allergic reactions to peanuts in patients aged 4 through 17 years. No set-aside was used in the awarding of this BPA. The period of performance for orders placed against the BPA extends through...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Adaptimmune LLC, a foreign-owned for-profit manufacturer. The BPA has a ceiling value of $5,525,200.00 and a period of performance ending on June 10, 2026. The BPA is for the procurement of TECELRA products and services. While the specific details of the contracted items are not provided, BPAs are typically used to establish a simplified method of filling anticipated repetitive...

The Blanket Purchase Agreement was awarded by the Department of Agriculture Agricultural Research Service Field Research Implementation and Information Delivery Pacific West Area to Nutrien AG Solutions, Inc. as a single-award contract vehicle. The BPA aims to support Account #1405730 at Nutrien AG in Hansen, Idaho from November 1, 2020 through September 30, 2025, with a potential value of $100,000. The base year runs from November 1, 2020 through September 30, 2021. Subsequent years run from...

The Defense Health Agency awarded a blanket purchase agreement to Progenics Pharmaceuticals Inc. to procure PILARIFY (PIFLUFOLASTAT F-18) injection, an imaging agent used in positron emission tomography scans to aid in the detection and localization of prostate cancer. The BPA has a potential value of $250,000 and period of performance through April 2027. Multiple firm fixed price call contracts have been placed against the BPA at various medical treatment facilities for delivery of PILARIFY...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Sanofi-Aventis U.S. LLC, a foreign-owned for-profit organization, with no set-aside used. The single-award BPA has a ceiling value of $5,000,000.00 and a period of performance from July 1, 2024, to June 30, 2026. The BPA is for the procurement of TZIELD, a pharmaceutical product. As a BPA, this contract provides a streamlined mechanism for the agency to order and obtain TZIELD from the...

The U.S. Department of Defense Uniformed Services University of the Health Sciences awarded a Blanket Purchase Agreement (BPA) to Spring Valley Laboratories, Inc. (SVL), a self-certified small disadvantaged business, for an Immunization Study on Rabbits (GP350MT SQ). The total potential value of the BPA is $125,000.00, with several individual BPA call orders issued under the agreement. The BPA call orders range from $4,662.92 to $15,000.00 in ceiling value and have firm fixed price pricing...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Day One Biopharmaceuticals, Inc. The single-award BPA has a ceiling value of $15,000,000.00 and a period of performance ending on March 7, 2026. The BPA is for the procurement of OJEMDA, though the specific products and services to be delivered are not explicitly stated in the provided information. As a BPA, this contract vehicle allows the agency to place orders for recurring...

This Blanket Purchase Agreement was awarded by the Department of the Army Medical Command to Nephron Sterile Compounding Center LLC on March 1, 2020, with a potential value of $2.5 million. The BPA is for specialized compounded intravenous solutions with no set-aside used. The period of performance extends through the last date to order of September 30, 2023. The BPA facilitates recurring orders for specific pharmaceutical products and supplies, including Phenylephrine HCI Injection,...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Advanced Accelerator Applications USA Inc., a large, foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The $23.4 million single-award BPA is under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of February 3, 2025. The BPA is for the procurement of LOCAMETZ and NETSPOT, two...

Biogen U.S. Corporation, a pharmaceutical and biotechnology company specializing in neurological disease therapies, was awarded a single-award Blanket Purchase Agreement (BPA) valued at $430,578.10 by the National Acquisition Center, a civilian federal agency, effective December 4, 2023, through October 29, 2025. This BPA, established under the Pharmaceuticals and Drugs General Services Administration (GSA) Schedule (FSS-61-IB), procures Spinraza, a pharmaceutical product indicated for the...